On the other hand, same vector dosesadministered in juvenile group resulted in stable high ARSB activity andmaintenance above or within the normal range throughout the follow-up time,suggesting that late gene therapy with AAV2/8 vector may be beneficial foreventual clinical application, since MPS VI patients are not normally diagnosedat birth. Here, ARSB is linked to mucopolysaccharidosis type 6.